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Identification of biomarkers associated with protection from developing diabetic complications is a 
prerequisite for an effective prevention and treatment. The aim of the present study was to identify 
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DIALONG (n = 71) cohorts. The DIALONG study also included 75 healthy controls. Plasma metabolites 
were measured using gas and/or liquid chromatography coupled to mass spectrometry. Lower 
hepatic fatty liver indices were significant common feature characterized NPs in both studies. 
Higher insulin sensitivity and residual ß‑cell function (C‑peptide) were also associated with NPs in 
pRoLonG. protection from diabetic complications was associated with lower levels of the glycolytic 
metabolite pyruvate and Apociii in pRoLonG, and with lower levels of thiamine monophosphate 




metabolism pathways to promote nucleotide biosynthesis in the liver. these processes might be 
linked to higher insulin sensitivity and lower liver fat content, and might represent a mechanism for 
protection from vascular complications in individuals with long‑term T1D.
The globally rising incidence and survival of type 1 diabetes (T1D) imposes a considerable socio-economic 
burden driven by the associated macro- (coronary artery disease, stroke, peripheral artery disease), and micro-
vascular (retinopathy, nephropathy, and neuropathy)  complications1,2. The Nordic countries have the highest 
incidence of T1D in the  world3. Although recent technological advances have improved strategies for insulin 
delivery, they neither prevent the disease progression nor protect from the chronic diabetic  complications4. 
Investigation of protective mechanisms may help to identify new targets for prevention of diabetic complications.
Lack of endogenous insulin due to an autoimmune destruction of the pancreatic ß-cells is a common feature 
of those with T1D. Chronic hyperglycaemia leads to metabolic adaptations in many cells, aiming to reduce glu-
cose transport and to maintain intracellular glucose concentrations within the physiological  range5,6. However, 
some cells and tissues with high energy demands, such as the endothelial cells, ß-cells and neurons, do not adapt 
their glucose transport efficiently enough, which results in increased intracellular glucose concentrations. In 
addition, a relative insulin deficiency stimulates gluconeogenesis in the liver and lipolysis in the adipose tissue, 
resulting in the release of glucose and free fatty acids, and, thereby further increasing the levels of circulating 
energy sources. A decade ago, Michael Brownlee hypothesized that intracellular energy overload would lead to 
the overproduction of superoxide in the mitochondria, leading to oxidative stress and predispose to diabetic 
 complications7. However, pharmacological interventions targeting these pathways in humans have failed to 
halt or prevent the development of diabetic complications. Hence, the key question regarding the mechanisms 
responsible for sustained resistance and protection of organs and cells from damage in individuals with diabetes 
remains unanswered. The Scandinavian PROLONG (PROtective genetic and non-genetic factors in diabetic 
complications and LONGevity) initiative in Sweden and Denmark was launched aiming to identify clinical, 
metabolic and genomic factors promoting protective mechanisms in individuals with long-term T1D who have 
escaped from the development of diabetic complications. The Norwegian DIALONG study of individuals with 
long-term T1D was set up to describe undiagnosed coronary artery disease (CAD) and joint stiffness after a 
duration of diabetes of more than 45  years8,9. In the present study, we aimed to characterize clinical and plasma 
metabolomic features associated with freedom from vascular complications in individuals with long-term T1D 
in two independent Scandinavian cohorts PROLONG and DIALONG.
Results
clinical characteristics. In total, 482 individuals with long-term T1D were included in the present anal-
yses, of whom 374 were non-progressors (NP) (PROLONG, n = 333; DIALONG, n = 41) and 108 were rapid 
progressors (RP) (PROLONG, n = 78; DIALONG, n = 30). Descriptive characteristics of NP and RP groups 
are shown in Tables 1 and 2. Age at onset of the PROLONG participants with T1D occurred in general after 
puberty (NP and RP, 17.5 ± 9.8 vs. 23.3 ± 14.4, p = 0.01) years, and of the DIALONG participants before or dur-
ing puberty (12.3 ± 6.0 vs. 10.4 ± 6.2 years, p = 0.17). Consistently in both cohorts, NPs were characterized by 
lower fasting plasma triglyceride levels (NP and RP, 0.8 ± 0.3 vs. 1.0 ± 0.5 mmol/L, p < 0.05 in PROLONG and 
0.7 ± 0.2 vs. 1.0 ± 0.5 mmol/L, p < 0.01 in DIALONG), and lower to a lesser degree by lower  HbA1c (7.6 ± 1.0 vs. 
9.0 ± 1.5%, p < 10–8 in PROLONG, and 7.3 ± 0.7 vs. 7.7 ± 0.8%, p = 0.02 in DIALONG). Reduced fatty liver indices 
were prominent features in participants free from vascular complications in both studies (fatty liver index (FLI), 
0.6 ± 0.7 vs. 0.8 ± 0.8, p = 0.01 and 0.5 ± 0.8 vs. 1.5 ± 1.5, p < 0.001, and hepatic steatosis index (HSI), 33.7 ± 4.8 vs. 
36.0 ± 5.8, p = 0.06 and 32.9 ± 3.7 vs. 37.2 ± 4.4, p < 0.001; in PROLONG and DIALONG, respectively).
GAD antibody positivity at the time of the studies (2011–2015) was less frequent among NPs than RPs 
(p = 0.02) in PROLONG, while there were no differences in DIALONG. Higher estimated glucose disposal rate 
(eGDR, NP and RP, 7.0 ± 2.3 vs. 5.7 ± 2.5, p < 10–5), reflecting a better insulin sensitivity, and more residual ß-cell 
function as assessed by fasting C-peptide (p = 0.03) were associated with lack of complications in PROLONG, 
but not in DIALONG. There was a strong negative correlation between eGDR and liver fat indices (PROLONG: 
eGDR and FLI ρ = − 0.54, p < 2.2e−16 (NP), and ρ = − 0.62, p = 3.4E−08 (RP); eGDR vs. HSI ρ = − 0.39, p = 1.6e−12 
(NP), and ρ = − 0.49, p = 4.2E−05 (RP); DIALONG: eGDR and FLI ρ = − 0.47, p = 0.002 (NP), and ρ = − 0.66, 
p = 7.0E−05 (RP); eGDR and HSI ρ = − 0.3, p = 0.06 (NP), and ρ = − 0.63, p = 1.8E−04 (RP)).
Encouraged by the low triglyceride concentrations in the NP group, we also measured the plasma apolipo-
protein CIII (APOCIII) levels in the PROLONG cohort, and there were slightly lower APOCIII levels in the 
NPs as compared to the RPs (p = 2.5e−03) (Table 3). The difference remained unchanged and significant after 
adjustment for  HbA1c levels (p = 0.02).
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Plasma metabolites in NPs and RPs. Univariate results from the metabolomics analyses in the PROLONG and 
the DIALONG cohorts are reported in the Supplementary Appendix. Untargeted metabolomics analyses in the 
PROLONG showed higher levels of serine (GC–MS) (p = 0.01), phenylalanine (LC–MS) (p = 0.01) and taurine 
(GC–MS) (p = 0.01) in the NP group compared to the RP group (Table 4). In addition, using the same GC–MS 
platform in the DIALONG, lower levels of erythritol, myo-inositol, pyroglutamate and cystine (p < 0.05) were 
observed in the NPs compared to the RPs (Table 4). In the targeted metabolite analyses of DIALONG, higher lev-
els of glycine (GC–MS/MS, p = 6.7e−03), serine (GC–MS/MS, p = 0.02), phenylalanine (GC–MS/MS, p = 0.03), 
and lower levels of thiamine monophosphate (LC–MS/MS, p = 0.02) were associated with NPs as compared to 
RPs (Table 5), and these differences remained significant after adjustment for  HbA1c. Furthermore, in the multi-
variable analyses (Table 6), including  HbA1c and fatty liver index, these metabolites were independently associ-
ated with NPs, apart from serine which is highly correlated with glycine  (r2 = 0.47, p = 5e−04). We further found 
lower directly measured plasma pyruvate levels in the NPs compared with the RPs (p = 0.01) in PROLONG 
(Table 3). However, this difference was no more significant after adjustment for  HbA1c (p = 0.06).
comparison of nps and Rps with healthy controls. Individuals with long-term T1D in DIALONG 
showed established features of increased lipolysis, including elevated levels of plasma glycerol (p = 0.004), long-
chain free fatty acids (p ≤ 0.01) and ß-hydroxybutyrate (p = 1.8e−06) (Supplementary Table 5) as compared to 
the healthy individuals. Significantly elevated levels of picolinic acid (p = 6.8e−06) were found in those with 
T1D as compared to the healthy controls by using targeted metabolite profiling (Table 7). Individuals with long-
term T1D who never developed major complications (NPs) had higher plasma levels of serine (p = 0.04) and 
Table 1.  Clinical characteristics of the PROLONG participants. Data are mean (sd). BP denotes blood 
pressure, NP non-progressors, RP rapid progressors. Linear regression models: Pa value = adjusted for center/
storage, sex, age, Pb value adjusted for center/storage, sex, age,  HbA1c. *Mann–Whitney test. **Median (IQR), 
or count (%).
Phenotype Number NP Number RP NP RP p  valuea p  valueb
Age [years] 322 74 58.1 (10.5) 45.1 (14.1)
Age at diagnosis [years] 322 74 17.5 (9.8) 23.3 (14.4) 0.01*
T1D duration [years] 333 78 40.5 (8.6) 21.6 (7.9)  < 0.0001  < 0.0001
Sex, male 333 78 144 (43%) 40 (51%) 0.25*
Smoking, current 311 71 7 (2%) 4 (6%) 0.25*
Hypertension 331 77 192 (58%) 53 (68%) 0.11*
Waist [cm] 313 67 51.6 (43.8) 77.4 (34.5) 0.04 0.18
Waist/Hip 313 67 0.9 (0.1) 0.9 (0.1) 0.07 0.19
BMI [kg/m3] 324 78 24.8 (3.8) 26.2 (4.7) 0.04 0.12
Systolic BP, sitting [mmHg] 328 76 130.6 (17.5) 126.9 (17.7) 0.19 0.45
Diastolic BP, sitting [mmHg] 328 76 75.5 (9.1) 79.1 (9.1) 0.17 0.27
GAD antibodies [number positive] 311 66 156 (50%) 44 (67%) 0.02
C-peptide [nmol/L]** 285 62 0.008 (0.003–0.015) 0.003 (0.003–0.014) 0.03 0.02
HbA1c [DCCT] 329 78 7.6 (1.0) 9.0 (1.5)  < 0.0001
Insulin dosage [units/day]** 218 55 36.5 (29.0–46.0) 57.0 (40.2–72.0)  < 0.001 5.0e−03
eGDR [mg/kg/min] 310 66 7.0 (2.3) 5.7 (2.5)  < 0.0001  < 0.0001
Triglycerides [mmol/L] 319 76 0.8 (0.3) 1.0 (0.5)  < 0.0001 0.02
HDL-C [mmol/L] 319 76 1.8 (0.6) 1.6 (0.6) 0.98 0.24
Cholesterol [mmol/L] 319 76 4.8 (0.8) 4.8 (0.9) 0.63 0.98
LDL-C [mmol/L] 319 76 2.6 (0.7) 2.7 (0.8) 0.91 0.30
eGFR [ml/min/1.73m3] 321 74 86.8 (15.6) 91.0 (30.0) 0.57 0.98
ASAT [U/L] 333 76 25.2 (8.9) 21.2 (8.2) 0.01 0.06
ALAT [U/L] 333 78 24.0 (11.7) 21.9 (9.8) 0.01 0.01
ASAT/ALAT 333 76 1.16 (0.42) 1.02 (0.31) 0.80 0.56
GGT [U/L] 332 78 28.2 (43.5) 34.6 (81.7) 0.10 0.33
Fatty liver index (FLI) 297 65 0.60 (0.71) 0.81 (0.77) 0.01 0.05
Hepatic steatosis index (HSI) 324 76 33.7 (4.8) 36.0 (5.8) 0.06 0.39
Retinopathy, n (%) – 78 – 54 (69%)
Nephropathy, n (%) – 78 – 41 (53%)
CVD, n (%) – 56 – 2 (3%)
Lipid treatments 180 57 102 (67%) 29 (51%) 0.54*
Antihypertensive treatments 180 56 70 (39%) 31 (55%) 0.04*
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reduced fatty liver index (p = 6.0e−03, and after adjustment for  HbA1c p = 8.7e−03) as compared to the healthy 
age-matched individuals (Table 7 and Supplementary Table 4).
Discussion
One of the main findings in the present observational study was markedly lower fatty liver index in both studies, 
and a significantly higher insulin sensitivity index in the PROLONG NPs as compared to RP patients. Recently, 
there have been numerous reports on an alarming increase in the prevalence of non-alcoholic fatty liver disease 
(NAFLD), reaching an estimate of almost 70% of individuals with T1D, but also in non-diabetic  individuals10. 
Accumulation of fat in the liver is associated with a four- to fivefold increased risk of macro- and microvascular 
 complications11–13. With the increasing rates of obesity, this may be further accompanied by increased insulin 
resistance, a phenomenon termed as “double diabetes”, which is characterised by impaired action of endogenous 
or exogenous insulin in the target tissues in individuals with T1D in a similar fashion as described in  T2D14.
Key components of the fatty liver index—triglycerides and waist circumference—are well established mark-
ers of insulin resistance. Our finding of elevated triglycerides in the RPs is in line with the Joslin Medalist and 
the Golden Years studies, which reported higher triglyceride levels in individuals with long-standing T1D and 
Table 2.  Clinical characteristics of the DIALONG participants. Data are mean (sd). nNP = 41,  nRP = 30. 
BP denotes blood pressure, NP non-progressors, RP rapid progressors. Linear regression models: Pa 
value = adjusted for center/storage, sex, age, Pb value adjusted for center/storage, sex, age,  HbA1c. *Mann–
Whitney test. **Median (IQR), or count (%).
Phenotype NP RP p  valuea p  valueb
Age [years] 61.1 (7.1) 61.5 (6.7)
Age at diagnosis [years] 12.3 (6.0) 10.4 (6.2) 0.17*
T1D duration [years] 48.8 (3.5) 51.1 (5.2) 0.02 0.07
Sex (male) 16 (39%) 13 (43%) 0.90*
Smoking, current 2 (5%) 1 (3%) 1.00*
Hypertension 26 (63%) 16 (53%) 0.54*
Waist [cm] 85.6 (10.4) 95.0 (13.2)  < 0.001 3.9e−03
Systolic BP [mmHg] 144.8 (19.5) 144.5 (17.2) 0.93 0.79
Diastolic BP [mmHg] 75.7 (8.6) 73.0 (6.6) 0.12 0.31
BMI [kg/m3] 24.6 (3.1) 27.4 (3.8) 1.7e−03 0.01
GAD antibodies [kE/L] 0.19 (0.45) 0.17 (0.59) 0.79 0.95
GAD antibodies (positive) 0 (0%) 0 (0%) n/a n/a
Anti-insulin 0.39 (0.56) 0.71 (1.0) 0.12 0.15
C-peptide [nmol/L]** Undetectable Undetectable n/a n/a
HbA1c [DCCT] 7.3 (0.7) 7.7 (0.8) 0.02
Insulin daily dosage [units/day]** 30.0 (24.0–38.0) 37.0 (34.0–45.8) 0.12 0.16
eGDR [mg/kg/min] 7.2 (1.8) 6.5 (2.2) 0.19 0.28
Triglycerides [mmol/L] 0.7 (0.2) 1.0 (0.5) 4.5e−03 6.7e−03
HDL-C [mmol/L] 2.2 (0.5) 2.0 (0.5) 0.11 0.18
Cholesterol [mmol/L] 5.1 (0.9) 4.9 (1.0) 0.52 0.89
LDL-C [mmol/L] 2.7 (0.8) 2.7 (0.8) 0.88 0.75
CRP [mg/L] 2.2 (2.4) 2.9 (2.9) 0.28 0.54
Creatinine [μmol/L] 69.2 (11.9) 81.2 (28.9) 0.02 0.09
eGFR [ml/min/1.73m3] 70.1 (14.4) 64.2 (16.4) 0.16 0.35
ASAT [U/L] 27.3 (8.9) 29.5 (10.7) 0.39 0.44
ALAT [U/L] 24.4 (11.8) 31.1 (14.7) 0.04 0.07
ASAT/ALAT 1.2 (0.3) 1.0 (0.2)  < 0.001 1.3e−03
GGT [U/L] 25.9 (17.7) 37.7 (29.0) 0.04 0.14
Fatty liver index (FLI) 0.5 (0.8) 1.5 (1.5)  < 0.001 4.6e−03
Hepatic steatosis index (HSI) 32.9 (3.7) 37.2 (4.4)  < 0.0001  < 0.001
Retinopathy, n (%) 29 (97%)
Nephropathy, n (%) 10 (33%)
CVD, n (%) 12 (40%)
Statins 14 (34%) 20 (67%) 0.01*
Beta-blocker 2 (5%) 11 (37%) 2.0e−03*
ACE/ARB 10 (24%) 21 (70%)  < 0.001*
Antiplatelet agent 5 (12%) 14 (47%) 3.0e−03*
Loop diuretics 1 (2%) 7 (23%) 0.02*
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 macroalbuminuria15,16. Also, the FinnDiane study reported similar  features17. Both the Golden Years and the 
Joslin Medalist studies proposed that elevated HDL cholesterol protects against cardiovascular diseases. In our 
cohorts, the differences in HDL cholesterol between NP and RP did not reach statistical significance, possibly 
because our RP groups included mostly patients with microvascular complications where HDL seemingly plays 
less of a role. Another explanation for the lack of association may be an absence of protective properties of HDL 
Table 3.  Directly measured metabolites in the PROLONG cohort. Data were winsorized before analyses, 
and statistical tests performed on log2-transformed data. NP non-progressors, RP rapid progressors. ns 
non-significant (p > 0.05). Linear regression models: Pa (adjusted for center/storage, sex, age), Pb (adjusted for 
center/storage, sex, age,  HbA1c).
Mean (SD)
Metabolite NP RP NP RP p  valuea p  valueb
APOC3 [mg/dl] 318 59 11.6 (3.9) 12.6 (5.9) 2.5e−03 0.02
Pyruvate [μM] 312 64 95.2 (28.9) 102.5 (27.9) 0.01 0.06
IGF1 [μg/L] 333 78 123.2 (42.3) 150.6 (48.4) ns 0.1
IGFBP1 [μg/L] 330 75 93.3 (44.5) 72.9 (40.8) 3.6e−03 ns
Glucagon [pg/ml] 312 64 15.3 (12.8) 15.0 (9.6) ns ns
Alanine [μM] 313 64 322.0 (58.1) 325.0 (68.0) ns ns
Lactate [μM] 311 64 916.1 (380.0) 909.3 (393.3) ns ns
Table 4.  Significant untargeted metabolites in the cohorts (NP vs. RP). Data were winsorized before analyses, 
and statistical tests performed on log2-transformed data. ns non-significant (p > 0.05). NP non-progressors, 
RP rapid progressors. nNP = 226,  nRP = 45 for PROLONG, 1nNP = 39,  nRP = 30: 2nNP = 40,  nRP = 30 for DIALONG. 
Linear regression models: Pa (adjusted for sex, age), Pb (adjusted for sex, age,  HbA1c), both models are adjusted 
for center/storage for PROLONG, b for effect size of binary group coefficient. 1 GC-MS, 2UHPLC.
PROLONG DIALONG
Metabolite ba bb p  valuea p  valueb ba bb p  valuea p  valueb
Serine1 0.2 0.1 0.01 ns 0.1 0.1 ns ns
Phenylalanine2 0.3 0.3 0.01 0.03 − 0.2 − 0.1 ns ns
Carnitine  C42 − 0.3 − 0.3 ns ns − 0.5 − 0.4 2.4e−03 9.1e−03
Carnitine  C52 − 0.1 − 0.1 ns ns − 0.6 − 0.6 6.1e−03 0.01
Erythritol1 – – – – − 0.6 − 0.5 4.3e−03 0.03
LPE C20:42 – – – – − 0.7 − 0.6 9.7e−03 0.03
Pyroglutamate1 0 0 ns ns − 0.3 − 0.3 0.01 0.03
Myo-inositol1 − 0.1 − 0.1 ns ns − 0.4 − 0.3 0.02 ns
Glutamate1 − 0.2 0 ns ns − 0.7 − 0.6 0.02 ns
Hydroxyproline1 − 0.2 − 0.1 ns ns − 0.5 − 0.4 0.02 0.05
Cystine3,1 − 0.1 − 0.1 ns ns − 0.6 − 0.5 0.02 0.03
Ornithine3,1 − 0.1 − 0.1 ns ns − 0.5 − 0.4 0.02 ns
Hippuric  acid2 – – – – − 0.6 − 0.5 0.02 ns
Carnitine2 – – – – − 0.1 − 0.1 0.03 ns
Cystine4,1 − 0.2 − 0.2 ns ns − 0.8 − 0.8 0.03 0.05
Creatinine1 − 0.1 − 0.1 ns ns − 0.5 − 0.4 0.03 ns
Table 5.  Top associated targeted metabolites in the DIALONG study. Data were winsorized before analyses, 
and statistical tests performed on log2-transformed data. NP non-progressors, RP rapid progressors.  nNP = 25, 
 nRP = 27. Linear regression models: Pa (adjusted for sex, age), Pb (adjusted for sex, age,  HbA1c). 1 Bevital GC–
MS/MS, 2Bevital LC–MS/MS. *Tot. thiamine is calculated as total of thiamine monophosphate and thiamine.
Mean (SD)
Metabolite NP RP p  valuea p  valueb
Glycine [μmol/L]1 314.4 (62.2) 274.6 (45.8) 6.7e−03 8.7e−03
Serine [μmol/L]1 127.1 (26.7) 112.4 (28.3) 0.02 0.03
Phenylalanine [μmol/L]1 62.6 (7.2) 58.0 (7.7) 0.03 0.04
Tot. thiamine* [nmol/L]2 10.5 (6.4) 15.1 (12.2) 0.03 0.04
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at the high  levels18. Therefore, the interpretation could be specifically challenging in T1D, in which HDL particles 
could also be atherogenic, if HDL is high. Lower levels of triglycerides in the NP group are compatible with an 
increased suppression of lipolysis as supported by findings of reduced APOCIII levels in the NPs; importantly, 
adjustment for  HbA1c did not change this result, confirming higher insulin sensitivity and stronger inhibition of 
lipolysis despite lower insulin dosage in NPs. These findings support a recent report demonstrating that serum 
APOCIII levels predict incident coronary artery disease independently from diabetes duration and HbA1c in 
individuals with T1D.
Another correlate of fatty liver index is gamma-glutamyltransferase (GGT), a membrane-bound enzyme, 
which is indicative of cell damage when elevated in the circulation and found significantly lower in the DIA-
LONG NPs. GGT plays a crucial role in regulation of the redox balance by metabolizing extracellular reduced 
glutathione to provide the amino acid cysteine for de novo synthesis of  glutathione19. Interestingly, we also 
observed high plasma levels of the non-essential amino acids, serine and glycine in the NP group, which were 
also negatively associated with fatty liver indices in the NP group (Figure S1). Glycine serves as an intermediate in 
the glutathione biosynthesis, although levels of this amino acid are not rate-limiting, whereas serine is a substrate 
Table 6.  Multivariate analysis with top associated targeted metabolites in the DIALONG study. Correlation 
between Serine and Glycine is 0.46 in all (p = 0.0005), 0.51 in RPs (p = 0.007) and 0.3 in NPs (ns). Data were 
winsorized before analyses, statistical tests performed on log2-transformed data. NP non-progressors, RP rapid 
progressors.  nNP = 25,  nRP = 27. Linear regression models: Pa (adjusted for sex, age, FLI), Pb (adjusted for sex, 
age, FLI,  HbA1c). 1 Bevital GC–MS/MS, 2Bevital LC–MS/MS.
Metabolite ba p  valuea bb p  valueb
Glycine1 6.6 0.01 7.6 0.01
Serine1 − 0.1 0.95 0.6 0.73
Phenylalanine1 11.5 0.01 15.0 0.01
Thiamine monophosphate − 4.7 0.01 − 5.5 0.01
Table 7.  Top associated targeted metabolites in the cohorts (patients with T1D vs. controls). Data were 
winsorized before analyses, and statistical tests performed on log2-transformed data. ns non-significant 
(p > 0.05), NP non-progressors, RP rapid progressors.  ncontrol = 27,  nNP = 25,  nRP = 27. Linear regression models: 
 Pa (adjusted for sex, age),  Pb (adjusted for sex, age,  HbA1c). 1 Bevital GC–MS/MS, 2Bevital LC–MS/MS.
Control T1D (NP + RP) NP RP
Metabolite Mean (sd) Mean (sd) p value (pa/pb) Mean (sd) p value (pa/pb) Mean (sd) p value (pa/pb)
Picolinic acid 
(nmol/L)2 35.4 (12.1) 53.2 (20.7)  < 0.0001/ < 0.001 57.0 (19.7)  < 0.0001/ < 0.001 49.7 (21.2) 1.2e−03/0.05
3-Hydroxyisobutyrate 
(μmol/L)1 17.0 (3.6) 21.4 (6.1)  < 0.001/ < 0.001 22.0 (6.0) 3.8e−04/0.01 20.8 (6.2) 7.9e−03/0.02
β-Hydroxybutyrate 
(μmol/L)1 60.0 (51.3) 212.6 (224.3)  < 0.0001/ < 0.001 202.3 (255.0) 3.1e−04/0.03 222.2 (196.2)  < 0.0001/ < 0.001
Nicotinamide 
(nmol/L)2 261.0 (92.1) 211.2 (61.2) 8.0e−03/ns 207.7 (50.0) 0.02/ns 214.4 (71.0) 0.04/ns
N1-methylnicotina-
mide (nmol/L)2 151.7 (76.3) 119.6 (71.2) 0.03/ns 108.5 (63.5) 8.2e−03/ns 129.9 (77.4) ns/ns
Serine (μmol/L)1 114.0 (17.0) 120.6 (28.0) ns/0.02 128.0 (26.7) 0.02/0.04 113.7 (27.7) ns/ns
Valine (μmol/L)1 242.4 (32.6) 256.9 (42.8) ns/2.0e−03 262.2 (46.6) ns/0.04 252.0 (39.1) ns/0.02
Leucine (μmol/L)1 118.3 (19.0) 125.0 (23.2) ns/8.6e−03 126.3 (23.5) ns/0.03 123.7 (23.3) ns/ns
Methionine (μmol/L)1 27.7 (2.9) 28.7 (5.2) ns/0.05 30.2 (5.6) ns/0.01 27.3 (4.5) ns/ns
Tot. homocysteine 
(μmol/L)1 11.2 (2.1) 10.9 (3.2) ns/0.03 10.5 (2.2) ns/ns 11.2 (3.9) ns/0.02
Quinolinic acid 
(nmol/L)2 375.2 (90.2) 375.5 (156.2) ns/0.01 350.3 (124.8) ns/ns 398.8 (179.6) ns/1.1e−03
Methylmalonic acid 
(μmol/L)1 1.2 (0.04) 1.2 (0.05) ns/ns 1.2 (0.06) ns/ns 1.2 (0.05) ns/8.7e−03
Histidine (μmol/L)1 73.6 (7.0) 76.6 (7.5) ns/ns 75.0 (7.5) ns/ns 72.2 (6.3) 0.02/ns
Glycine (μmol/L)1 287.5 (80.7) 294.1 (55.2) ns/ns 314.1 (58.3) 0.02/ns 275.6 (45.8) ns/ns
Phenylalanine 
(μmol/L)1 62.9 (8.0) 61.2 (7.7) ns/ns 63.6 (7.1) ns/0.03 58.9 (7.6) ns/ns
Kynurenine (μmol/L)1 2.5 (0.3) 2.5 (0.4) ns/ns 2.5 (0.3) ns/ns 2.5 (0.4) ns/7.0e−03
3-Hydroxykynurenine 
(nmol/L)2 42.4 (11.8) 48.8 (18.9) ns/ns 46.0 (13.4) ns/ns 51.3 (22.9) ns/0.04
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for synthesis of both cysteine and glycine in the glutathione backbone. Reduced levels of serine have previously 
been linked to NAFLD in individuals with  T2D20, while elevated serine levels is also a common feature associated 
with  cancer21. Serine is also an intermediate in sphingolipid synthesis. Lower serine levels in RP may suggest 
increased incorporation of this amino acid into lipids, including ceramides and other compounds that have been 
shown to accumulate in NAFLD and insulin  resistance22. The NP group had also higher serine levels compared 
with the control group without diabetes. Moreover, glycine and serine are biosynthetically linked, and serine 
can be converted to glycine in the folate cycle, which, in turn, fuels carbons for nucleotide synthesis. The folate 
cycle is depending on the pentose phosphate pathway (PPP), which plays a key role in supplying intermediates 
for nucleotide synthesis and reducing equivalents to control the redox  balance23.
A key metabolite that can help to reduce oxidative stress by electron donation is NADPH, which is largely 
generated by the PPP in cells with high energy demands, such as the hepatocytes and the erythrocytes. Genera-
tion of precursors (glyceraldehyde 3-phosphate, ribose-5-phosphate and erythrose 4-phosphate) for nucleotide 
biosynthesis is a main function of PPP. In situations of intracellular fuel overload, shunting glycolytic interme-
diates into the PPP yields a relative energy loss in combination with an improved antioxidant and restorative 
capacity, via elevated cellular NADPH  levels24.
In support of an active PPP, in the NPs we observed lower levels of the vitamin B1 (thiamine) derivative, 
which potentially could indicate an elevated utilization of thiamine in the NPs. Thiamine is an essential cofac-
tor of the PPP, which generates NADPH and other phosphates by translocases. Reduced levels of thiamine have 
previously been associated with an increased risk of complications in individuals with T1D and  T2D25,26. Thia-
mine deficiency is common in diabetic patients and supplementation with benfotiamine, a synthetic thiamine 
activator, has been shown to prevent the development of diabetic neuropathy, nephropathy and retinopathy 
in experimental diabetic  animals27,28. However, supporting human data are still  lacking29. Beneficial effects of 
thiamine monophosphate administration have also been demonstrated in a number of neurological disorders 
including Alzheimer disease and  epilepsy30.
Additionally, we observed higher levels of the aromatic amino acid phenylalanine in NP patients. There is 
accumulating evidence showing a link between branched-chain and aromatic amino acids including valine, leu-
cine, isoleucine, phenylalanine, and tyrosine with insulin resistance and T2D  risk31. The association of elevated 
phenylalanine levels with relative protection from complications observed in our study might hence seem to 
be somewhat discordant with these findings. The fact that valine and leucine levels did not differ in NPs vs. 
RPs could suggest that phenylalanine might play a unique role in the metabolism that is different from what is 
seen in insulin resistance. In this context, the question whether generated in the PPP erythrose-4-phosphate is 
preferentially utilized as a precursor in the synthesis of the amino acid phenylalanine. This is supported by the 
lower levels of erythritol in the DIALONG NPs, which is recently  shown32, is produced in the PPP by reduction of 
erythrose-4-phosphate to erythritol-4-phosphate and further released in the form of erythritol. Notably, elevated 
levels of erythritol have been reported to be associated with progression to  T2D33, development of retinopathy 
in  T2D34 and progression to microalbuminuria in  T1D35.
We observed decreased pyruvate in the NP group, which could support the shift of glycolysis towards the 
PPP. Phenylalanine and serine have been ascribed a role as allosteric inhibitors and activators, respectively, of 
pyruvate  kinase36. This is in line with the Joslin Medalist study showing upregulation of pyruvate kinase in the 
kidney biopsies from individuals with more than 50 years of T1D without kidney  disease37. Recently, proteomics 
analyses of plasma identified enrichment of biomarkers from the glycolytic pathways, pentose phosphate- and 
pyruvate metabolism in the T1D Medallists that were protected from chronic kidney  disease38. Pyruvate kinase is 
activated by insulin, and whether phenylalanine and serine may counteract the insulin deficiency-related reduc-
tion in glycolytic flux remains to be established. Given that there were no differences in the levels of lactate and 
alanine between NPs and RPs, which would be expected in the case of increased glycolytic flux, another possible 
explanation for the reduced pyruvate levels could be its utilization in one carbon metabolism—another essential 
pathway regulating nucleotide biosynthesis.
In addition, in the DIALONG T1D cohort we found elevated levels of picolinic acid, which is produced 
from tryptophan in the kynurenine pathway. These results support recent findings of an  HbA1c-independent 
elevation of the kynurenine pathway intermediates in the urine of children with  T1D39. The authors suggested 
that the kynurenine pathway could be responsible for the neuronal damage observed in T1D children and 
young  adults40. The cytoprotective effects of the kynurenine pathway has been linked to neuronal DNA  repair41. 
Complete tryptophan oxidation results in the de-novo synthesis of the intracellular pyrimidine—nicotinamide 
adenine dinucleotide  (NAD+).  NAD+ serves as a rate limiting substrate for the master sensors of energy metabo-
lism, sirtuins (SIRTs), and is responsible for the DNA repair, Poly (ADP-ribose) polymerases (PARPs)42. During 
recent years, boosting of NAD + levels in vivo has been suggested as a means to combat a number of age-related 
disorders and to prolong healthy  lifespan43. Moreover, we found lower levels of NAD + precursors, nicotinamide 
and methylnicotinamide, in individuals with T1D, as compared to healthy controls. Hence, these data may sug-
gest an alteration in the branching point of the kynurenine pathway, which either buds off into synthesis of the 
neuroprotective picolinic acid, or the neurotoxic quinolinic acid, which is later metabolized to nicotinamide. 
Notably, the neuroprotective effects of picolinic acid is believed to result from the ability of this metabolite to 
chelate iron and  zinc44, thereby antagonizing the cytotoxic quinolinic acid.
Our data of significantly higher insulin sensitivity, as estimated by the eGDR-index, in the PROLONG NPs 
support the idea of higher synthesis of nucleotides in the liver described to be controlled by  insulin45. A number 
of studies in  healthy46,47 and  T1D48 individuals suggested that fatty liver indices may serve as surrogate markers 
for abnormal insulin sensitivity. The present findings of a strong inverse correlation between insulin sensitivity 
and liver fat indices are in line with a recent study from the FinnDiane Study Group reporting that obese long-
term T1D with relatively few complications had higher insulin sensitivity of hepatic glucose production and 
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insulin sensitivity to lipolysis, and lower liver fat content measured with proton magnetic resonance spectroscopy 
as compared to age-matched healthy  individuals49.
We did not detect differences in insulin sensitivity between NP and RP in the DIALONG study. One explana-
tion, however, could be a selection bias for survival in our study as RPs in the DIALONG were older, had longer 
diabetes duration with lower  HbA1c and lower prevalence of hypertension. Better insulin sensitivity in long-term 
DIALONG RPs would be in agreement with the recent report from the Swedish National Diabetes Registry 
showing gradually increased risk of CVD-related death with declined  eGDR50. Nevertheless, the DIALONG NPs 
demonstrated better insulin sensitivity for the given level of liver fat as compared to RPs or healthy individuals, 
supporting an overall better insulin sensitivity in NPs.
Finally, we detected nearly twofold higher levels of residual C-peptide in PROLONG NPs, which could be a 
plausible explanation for the protection against  complications51. This, however, was not replicated in the DIA-
LONG study, which included individuals with an earlier age of T1D onset, and absence of endogenous insulin 
production.
Limitations. Although PROLONG and DIALONG represent large studies of individuals with long-term 
T1D who never progressed to diabetic complications, the sample size is still limited. Metabolomics analyses were 
conducted using two analytical platforms, of which targeted metabolomics clearly represents the most reliable 
assessment of metabolite quantities. Replication in independent cohorts including entire population of people 
with T1D and information on vascular complication status using the same platform is an important next step.
future perspectives. Present findings highlight importance of future analyses of biomarkers linking liver 
metabolism and vascular complications in diabetes. Such analyses may include, for example, the possible role 
of serological biomarkers of endothelial dysfunction such as Endocan Serum Levels in Patients with Non-Alco-
holic Fatty Liver Disease with or without Type 2  Diabetes52.
In conclusion, our data suggest that shunting of glycolytic substrates in the liver towards the PPP and one 
carbon metabolism to promote nucleotide synthesis is potentially beneficial for the protection against vascular 
complications in individuals with long-term T1D as schematised in Fig. 1. These processes might be linked to 
Figure 1.  Schematic representation of the proposed mechanisms underlying protection from disease 
progression to vascular complications in patients with long-standing T1D. Higher insulin sensitivity and lower 
glucose levels (measured with  HbA1c), and also lower accumulation of fat in the liver characterize patients with 
long-term T1D who never progress to vascular complications (NPs). In the liver cell, glycolytic intermediates are 
actively shunted into the pentose-phosphate pathway (PPP) as indicated by reduced essential cofactor thiamine, 
increased phenylalanine and reduced erythritol. Generated NADPH is used in reductive biosynthesis of 
glutathione and detoxification processes to maintain antioxidant capacity. Ribose-5-phosphate (R5P) generated 
in PPP, and serine, glycine and pyruvate generated in glycolysis are used in the one carbon metabolism and 
nucleotide biosynthesis to improve restorative capacity. Metabolism of essential amino acid tryptophan 
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better insulin sensitivity and lower fat accumulation in the liver. Further studies investigating cellular levels of 
the metabolites and their genomic regulation by insulin are needed.
Methods
Study participants. Information on the PROLONG eligibility criteria and complication status was based 
on initial electronic hospital  records53. Recruitment of the participants was initiated at the Scania University 
Hospital, Malmö, Sweden, in February 2011. The recruitment continued at the Karolinska University Hospital, 
Danderyd Hospital and South Hospital in Stockholm, Sunderby Hospital in Luleå, University Hospital of Umeå, 
Sahlgrenska University Hospital in Gothenburg, all in Sweden, and the Steno Diabetes Center Copenhagen 
(SDCC), Gentofte, Denmark. The last PROLONG study visits were conducted at the SDCC in 2015. Individuals 
with T1D were classified based on their diabetes complication status. Non-progressors (NPs) were defined as 
those with diabetes duration of more than 30 years and who did not develop any major complications (diabetic 
nephropathy, proliferative retinopathy, myocardial infarction, stroke or chronic foot ulcer), whereas rapid pro-
gressors (RPs) were defined as those, who developed any of the above-mentioned complications within 25 years 
of diabetes duration. NPs who prior to or at the PROLONG study visit were diagnosed with any of the above-
mentioned complications were designated “late-progressors” and excluded from the present analyses.
DIALONG is a Norwegian study of individuals with long-term T1D with a disease duration of more than 
45 years (n = 103) and age-matched healthy controls (n = 75). The DIALONG study aims to investigate the preva-
lence of and risk factors for CAD and joint stiffness in older T1D individuals. The design and recruitment 
protocols for the DIALONG study have been published in detail  previously8. Both the PROLONG and the 
DIALONG studies were approved by the local ethics committees (PROLONG-Sweden, Regional Ethics Review 
Board, Department 1, Lund, Sweden, Dnr 777/2009, PROLONG-Denmark, The Capital Region Ethics Commit-
tee, Hillerød, Denmark, Dnr H-2-2013-073, DIALONG, South-East regional health authority, panel D, Norway, 
2014/851; 2019/28,968, for data analysis of both studies in UiB, West regional health authority, Norway, REK-
2019/1,324) and conducted in accordance with local institutional and national regulations.
Definition of diabetic complications. Diabetic nephropathy was defined as the presence of (1) macroalbumi-
nurea ≥ 200 µg/min in a timed overnight urine collection, (2) an albumin/creatinine ratio > 300 mg/g as mac-
roalbuminurea, or < 300 mg/g or > 30 mg/g as microalbuminuria in at least two out of three consecutive urine 
collections/morning urine samples (PROLONG-Denmark, DIALONG) or based on a documented diagnosis of 
diabetic kidney disease (PROLONG-Sweden). Proliferative diabetic retinopathy was assessed with fundus pho-
tography and defined as the presence of proliferative retinopathy in at least one eye and/or laser therapy (panreti-
nal photocoagulation), or non-traumatic blindness. CVD was defined as non-fatal myocardial infarction and/
or stroke (haemorrhagic or ischemic) (PROLONG-Sweden, PROLONG-Denmark) and balloon angioplasty or 
coronary artery bypass surgery (DIALONG).
procedures and measurements. In the PROLONG study, participants fasted overnight (> 8 h) and were 
instructed not to take their medication in the morning of the visit. Trained diabetes research nurses and bio-
medical analysts performed the physical examination following standard operating procedures. On the day of 
the examination, a signed informed consent was obtained, and blood and urine samples taken. The participants 
were also asked to fill out a detailed questionnaire. These self-reported records were then validated by the dia-
betes nurse at the clinical research visit and this information was stored in a database at the Scania University 
Hospital, Malmö, Sweden, and at the Trial Partner Data Management, Region Midtjylland in Denmark.
Questionnaires. Questionnaires were mailed to each participant prior to the clinical visit. At the SDCC, the 
questionnaire was also accessible electronically. The questionnaire included sections regarding personal medical 
history, complication status, family history of diabetes, education, physical activity, diet, smoking, psychosocial 
health and social status. Female participants were asked for details concerning pregnancy. Questionnaires were 
controlled by the research nurse, and the data were checked for outliers, nonsense values and cleaned before 
uploaded to the study database. In Sweden, all data obtained by questionnaires was transferred to the database at 
the Scania University Hospital in Malmö for central error detection. In Denmark, questionnaire data was veri-
fied at SDCC and stored at Trial Partner Data Management, Region Midtjylland.
Anthropometric measurements. Height was measured to the nearest millimetre. Weight was measured in 
light indoor clothing, without shoes, to the nearest 0.1 kg. Clothes were estimated to weigh 0.5 kg, which was 
deducted from the total weight. Body mass index (BMI) was calculated according to the formula weight (kg)/
height2 (m). Waist and hip circumferences were measured at the mid-point between the lower costal margins 
and the level of the anterior superior iliac crest to the nearest millimetre with the participant in a relaxed, stand-
ing position using standard measuring tape. Systolic and diastolic blood pressure was measured using calibrated 
equipment. The patient was placed in a chair and after 10 min rest, blood pressure was measured using the mean 
of two measurements.
Biochemical measurements. The blood samples were analysed at the clinical chemistry laboratories at the par-
ticipating centres. Serum C-peptide and plasma GAD65 auto-antibodies (GAD ab) were measured by elec-
trochemiluminescence-immunoassay/ECLIA and immunometric ELISA, respectively, at the Department of 
Clinical Chemistry in Malmö, Sweden. Serum IGF-1 was determined by RIA after separation of IGFs from insu-
lin-like growth factor binding proteins (IGFBPs) by acid ethanol extraction and cryoprecipitation. To minimize 
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interference of remaining IGFBPs a truncated form of IGF-1 [des(1–3) IGF-1] was used as  radioligand54, with 
intra- and inter-assays coefficient of variation of 4% and 11%, respectively. Serum IGFBP-1 concentrations were 
determined by  RIA55, with intra- and inter assays coefficients of variation of 3% and 10%, respectively. Creatinine 
was measured using enzymatic, colorimetric methods and albumin using immunoturbidimetric methods in the 
first morning urine sample to calculate the albumin-creatinine ratio (ACR). Urine and plasma samples were 
stored at − 80 °C for further analyses. Insulin dosage was self-reported and the cumulative daily insulin doses 
were calculated based on the self-reported questionnaire.
Estimated metabolic parameters. The albumin/creatinine ratio was calculated using the formula: (U-albu-
min mg/l × 8.84)/(U-creatinine (μmol/l)/1,000). eGFR was calculated using the following CKD-EPI formula: 
eGFR = 186 × serum  creatinine−1.154 × age−0.203 × (0.742 if female). VLDL cholesterol (VLDL-C) was calculated 
using the formula: VLDL-C = triglycerides (mmol/l)/2.2, if the triglyceride values were ≤ 5.05 mmol/l. LDL choles-
terol was calculated using the Friedewald’s equation (LDL-C = TC–VLDL-C–HDL-C mmol/l), and the estimated 
glucose disposal rate (eGDR) based on the formula eGDR = 21.158 + (− 0.09 × waist [cm]) + (−3.407 × hyper-
tension [yes = 1/no = 0]) + (− 0.551 × HbA1c [%]), where hypertension was defined as a systolic blood pres-
sure > 140 mmHg or a diastolic blood pressure > 90 mmHg or the use of antihypertensive  medication56. Hepatic 
steatosis index (HSI) was calculated using the formula: HSI = 8 × (ALAT/ASAT) + BMI + (2 if female)57, and fatty 
liver index (FLI) was defined as FLI = 100 × log [0.953 × ln(triglycerides) + 0.139 × BMI + 0.718 × ln(GGT) + 0.0
53 × waist – 15.745], where log(x) = 1/1 + e−x58. For the DIALONG study these procedures have been published 
 previously8.
Metabolomics. Plasma metabolites were determined using gas chromatography/time-of-flight mass spec-
trometry (GC/TOF–MS) (LECO Pegasus III TOF electron impact MS, LECO Corp., St. Joseph, MI)59,60 and 
reverse-phase ultra-high performance liquid chromatography/quadrupole time-of-flight mass spectrometry 
(UHPLC/QTOF-MS) (1,290 Infinity UPLC/6,550 iFunnel Q-TOF, Agilent Technologies, Santa Clara, CA) 
(DIALONG and PROLONG) in both positive and negative electrospray ionization  mode61. Variation within 
each batch was corrected by using stable isotope labelled internal  standards62. Samples or metabolites with more 
than 30% missing values (n = 8) were removed. The PROLONG samples were split into three batches, with the 
first two batches including samples from the Swedish participants and the third batch only samples from the 
SDCC. It I of note that the SDCC samples for GC were run 7 months after the Swedish samples (2015), while 
SDCC samples for UHPLC were run a year after Swedish samples (2015 and 2016). The UHPLC method was 
run over 6 months after GC, with the exact time difference dependent on the batch. However, data were adjusted 
for batch effects (between-day analysis) using the COMBAT  algorithm63. In addition, targeted metabolomics on 
the DIALONG cohort was performed at Bevital (www.bevit al.no) using GC–MS/MS (panel B) and LC–MS/MS 
(panel D).
Statistical analyses. All raw data were inspected for quality and distribution, and the outliers were 
removed using the MAD-method64 adjusted for non-symmetric distributions. All metabolite data and non-
normally distributed clinical variables were log2-transformed before analysis. Data used in correlation analyses 
were mean-centred and log2-transformed. Clinical categorical data were compared using Pearson’s chi-square 
test. The group medians were compared using Mann–Whitney U-test. Linear regression models were used to 
study the association of metabolites and complication group status corrected for covariates: age, sex, recruiting 
centre, year of visit, and  HbA1c where appropriate. All analyses were performed using R, version 3.4.4 and rel-
evant packages. Statistical tests were two-sided with a significance level of p < 0.05.
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